Rapid escalation of cholesterol-lowering treatment to prevent repeat heart events
Rapid Escalation of LipiD Lowering Therapy to Reduce RecUrrent Cardiovascular Event (REDUCE) : All Comers Study
This project will try frequent LDL-C checks and quicker increases in lipid-lowering medicines for adults with recent or chronic coronary artery disease to help them reach LDL goals and reduce repeat heart problems.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Chinese University of Hong Kong Academic / other |
| Locations | 1 site (Shatin, New Terrritories) |
| Trial ID | NCT07311941 on ClinicalTrials.gov |
What this trial studies
This observational registry will follow adults with atherosclerotic acute coronary syndrome or chronic coronary syndrome and implement more frequent LDL-C monitoring with earlier titration of lipid-lowering therapy. Participants will have repeat blood tests around 6–8 weeks after medication changes and clinicians will adjust statins and add-on non-statin agents as needed. The registry will record adherence, treatment changes, LDL-C levels over time, and recurrent cardiovascular events in a real-world hospital setting. The work is led by the Chinese University of Hong Kong at Prince of Wales Hospital and aims to address local barriers such as therapeutic inertia and limited resources.
Who should consider this trial
Good fit: Adults over 18 with atherosclerotic acute coronary syndrome or chronic coronary syndrome who can provide informed consent are the intended participants.
Not a fit: Patients with non-atherosclerotic causes of ACS, life expectancy under six months, severe psychiatric or neurological disorders, or cirrhosis may not receive benefit from this approach.
Why it matters
Potential benefit: If successful, this approach could help patients reach LDL-C targets sooner and lower their risk of repeat heart attacks or other cardiovascular events.
How similar studies have performed: Randomized trials have shown that intensive LDL-C lowering reduces cardiovascular events, but programs that focus on rapid, frequent monitoring and titration in routine clinical practice are less well studied.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age \>18 * (Cohort 1) Diagnosis of acute coronary syndrome due to atherosclerotic coronary artery disease * (Cohort 2) Diagnosis of chronic coronary syndrome due to atherosclerotic coronary artery disease Exclusion Criteria: * Inability to provide valid consent by the patient or his legal guardian * Diagnosis of ACS due to other causes than atherosclerotic coronary artery disease. * Psychiatric or severe neurological disorder, cirrhosis, or active malignancy leading to a life expectancy \< 6 months.
Where this trial is running
Shatin, New Terrritories
- Prince of Wales Hospital — Shatin, New Terrritories, Hong Kong (Recruiting)
Study contacts
- Study coordinator: Guangming Tan
- Email: xjldaniel@gmail.com
- Phone: 852-35051518
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.